The aim of this study was to evaluate the role of the number of primary lymphocyte subpopulations in predicting outcome and severity in patients with COVID-19. Hospitalized patients with confirmed SARS-CoV-2 infection were included and classified according to in-hospital mortality (survivors/non-survivors) and the need for maximum ventilation/oxygen support. (dangerous/not dangerous). Demographic, clinical, laboratory and serum lymphocyte subpopulations were analyzed retrospectively. A total of 160 patients were retrospectively included in the study. The T cell subset (total CD3+, CD3+CD4+, CD3+CD8+, CD3+CD4+CD8+ double positive [DP] and CD3+CD4CD8- double negative [DN]) absolute counts decreased in non-survivors and patients with severe disease. is compared with survivors and non-severe patients (P < 0.001).
4 mL (3 mL min.) Whole blood in 2 Lavender Top (EDTA) tubes. Ship immediately at 18â€“22Â°C within 24 hours. DO NOT REFRIGERATE OR FREEZE. Specify time and date of sample draw along with clinical details on test request form.
Sample Daily by 9 am; Report Same day
This test is designed for enumerating the percentage and absolute counts of lymphocyte subsets (TBNK). In confirmed COVID 19 patients CD3+CD4+ and or CD3+CD8+ lymphocyte counts can be used as an aid in determining the elevated risk of intubation with mechanical ventilation, and the risk of mortality in conjunction with clinical findings and the results of other laboratory tests. CD4 and CD8 T-cells are important for triggering the antibody response and viral killing respectively. Several published studies have shown that individuals with COVID 19 typically exhibit a decrease of CD4 and or CD8 counts with increasing disease severity.